RecruitingPhase 2Phase 3NCT07272772

Colon Cancer Diagnosis With FAPI-PET Imaging

Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients With Colon Cancer

Sponsor

Turku University Hospital

Enrollment

100 participants

Start Date

Oct 9, 2024

Study Type

INTERVENTIONAL

Conditions

Colon Cancer

Summary

Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool. The objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of PET scan called FAPI-PET — which uses a radioactive tracer that attaches to cancer-associated cells — to improve the detection of colon cancer spread to nearby lymph nodes and other sites before or after surgery. **You may be eligible if...** - You have been diagnosed with primary colon cancer and there is concern about possible lymph node spread seen on a CT scan - You have colon cancer with potentially curable spread (like liver or lung metastases) - You are being monitored after colon cancer treatment and there is suspicion of recurrence on CT or through rising CEA levels - You are in adequate overall health for a PET scan procedure **You may NOT be eligible if...** - You are unable to undergo PET/CT imaging - You are pregnant or breastfeeding - You have another active cancer that could confuse imaging results - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.